These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34862071)

  • 1. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study.
    Di Lena É; Hopkins B; Wong SM; Meterissian S
    Surgery; 2022 Mar; 171(3):666-672. PubMed ID: 34862071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.
    Minami CA; Kantor O; Weiss A; Nakhlis F; King TA; Mittendorf EA
    J Am Coll Surg; 2020 Oct; 231(4):434-447.e2. PubMed ID: 32771654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
    Iles KA; Thornton M; Park J; Roberson M; Spanheimer PM; Ollila DW; Gallagher K
    Am Surg; 2022 Mar; 88(3):471-479. PubMed ID: 34587799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
    Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
    Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
    Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
    Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use.
    Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R
    J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of early breast cancer during the COVID-19 pandemic in Brazil.
    Cavalcante FP; Novita GG; Millen EC; Zerwes FP; de Oliveira VM; Sousa ALL; Freitas Junior R
    Breast Cancer Res Treat; 2020 Nov; 184(2):637-647. PubMed ID: 32803637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
    McGuire KP; Hwang ES; Cantor A; Golshan M; Meric-Bernstam F; Horton JK; Nanda R; Amos KD; Forero A; Hudis CA; Meszoely I; De Los Santos JF
    Ann Surg Oncol; 2015 Jan; 22(1):75-81. PubMed ID: 25059792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.
    Thompson CK; Lee MK; Baker JL; Attai DJ; DiNome ML
    Ann Surg; 2020 Aug; 272(2):e96-e97. PubMed ID: 32675509
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.